Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vaccitech Plc ADR (NQ: VACC ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Nov 6, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vaccitech Plc ADR Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer November 06, 2023 From Barinthus Biotherapeutics Via GlobeNewswire Investigational Immunotherapy Treatments Offering Promise in Treating Pancreatic Cancer as Risk Factors Rise September 26, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:VACC),(NASDAQ:BPTS),(NASDAQ:RNAZ),(NYSE:BMY) EQNX::TICKER_END Via FinancialNewsMedia Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023 September 13, 2023 From Vaccitech plc Via GlobeNewswire Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments August 10, 2023 From Vaccitech plc Via GlobeNewswire Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B June 21, 2023 From Vaccitech plc Via GlobeNewswire Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody June 21, 2023 From Arbutus Biopharma Corporation Via GlobeNewswire Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy June 12, 2023 From Vaccitech plc Via GlobeNewswire Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favorable Tolerability and Immunogenicity Profile April 17, 2023 From Vaccitech plc Via GlobeNewswire Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B March 28, 2023 From Vaccitech plc Via GlobeNewswire Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments March 24, 2023 From Vaccitech plc Via GlobeNewswire Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions March 20, 2023 From Vaccitech plc Via GlobeNewswire Vaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific Officer January 30, 2023 From Vaccitech plc Via GlobeNewswire Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments November 10, 2022 From Vaccitech plc Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.